Member Info for Bella6532

Nothing is being done with regard to Covid...
More duff FB posts written by IF... Advertising!!!!
FF is produced in batches on production schedule and FF+O is produced on min order basis.
DSM does not manufacture either its all outsourced. Covid lockdown interrupted supply chains hence production delays.
Nothing new in this RNS apart from patent confirmations which are quite telling.

Vectura merged with Skyepharma in 2016. Skyepharma is now the oral business unit of Vectura... It certainly would tick some boxes. Vectura/Skyepharma have regulatory help service too plus manufacturing and supply chain (global)

News tomorrow me thinks...think they just put that drop in price out as a signal.. RNS probably lodged for tomorrow morning...or is that what they always say... Insert little smile and wink here...

Sorry.. They buy through holding company.. Big fingers, little phone and damn pre-emptive thingy... Sigh...

Yes I think our yankie boys are still buying. The buy through the hiding company and then distribute to their other companies. Those companies only have very small percentages right now. Its their way of spreading tax burden when profits made and declared. I had own companies in US some years back and did the same. Traded through holding company but had 3 other companies to which profits and commissions were paid. It's pretty standard in the US and back then it cost around $300 to register a new company no questions asked.

https://www.ncbi.nlm.nih.gov/books/NBK286004/Peer review is just that.. A review of data issued and then they try and pull holes in it to make sure it stacks up. Like it or not we have to be seen to be going down this route whether or not we might be in serious talks with Pharmas and Regulatory Authorities.
Fear not guys, the science will hold up...Synairhen have been in this game for too long to be putting forward duff data...

Frank09.. Thank you for that explanation...publication will be good for the scientists and their recognition but as you say Pharma will be looking at the raw data which they will be quite capable of interpreting. I assume they will have access to both Covid and COPD data whereas only Covid has been released for peer review...

Rdr...he mentions shot or transfusion....
An injection in US English is a shot...so it could be to do with the new combo trial Remdesivir/Interferon by injection (results in the fall (Autumn) and the transfusion bit could be referring to blood plasma (FDA have approved some uses).
https://www.nih.gov/news-events/news-releases/nih-clinical-trial-testing-remdesivir-plus-interferon-beta-1a-covid-19-treatment-begins

https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma

Now 218/224

Repost below and question:
'Already talking to pharma's for the COPD programme.'...is that the real reason the unblinded early???? Perhaps said Pharmas wanted to see both Covid and COPD results. Pharmas won't need 'written up' results...the peer review will be putting the results into a format best suited for publishing.

'We need to partner with a big pharma to talk to the markets and governments for Covid roll-out.' mmm! note the wording Partner...this means they need Pharma clout to bring in the large orders not for distribution.
Because he then says...'We are already in talks with a distribution company'.
Production would then depend on who they partner with...Pharma in house or Pharma using OEM.
Thanks for putting it up again CW25...

https://www.bloomberg.com/news/videos/2020-07-22/-bloomberg-surveillance-full-show-07-21-2020-video
Watch from 22 mins in - 28 mins.
Scanned the internet and have now found the full extract of Richards interview on Bloomberg - 21st July.
If you haven't already watched it do.
Many things to take from it:
'Already talking to pharma's for the COPD programme.'
'There is a cluster of them'. and then.. 'there are plenty of them'.
'We need to partner with a big pharma to talk to the markets and governments for Covid roll-out.'
'We are already in talks with a distribution company'
'We are in talks with the FDA/EMA'

If you weren't convinced to hold you will be after watching that again!

'Today we are announcing that sales and profit for the full year are expected to be significantly ahead of market expectations. Revenue growth is now expected to be between 17% and 19% with PBT in the region of £130m-£150m. The improvement in expectations is supported by stronger than anticipated underlying demand and the continuation of the beneficial returns profile highlighted in our last trading statement.'

Well they certainly kept it in a tight range all day. Flat as a pancake... They're really having to work at getting these large ii orders filled without letting SP move too sharply up or down. It really is starting to feel like a stretched piece of kni-ker elastic waiting to be let go...

https://www.cebm.net/covid-19/drug-vignettes-interferons/

Avonex is already has FDA approval.

Is one of my candidates for partnership in US..

http://ww1centenary.oucs.ox.ac.uk/body-and-mind/the-spanish-influenza-pandemic-and-its-relation-to-the-first-world-war/

Nice hefty end of day and late trades... Including 2 x £2m

Do you not think he was referring to Merck who are German... As its their injectable interferon in the trial..

Bruce, they've covered themselves in the Additional Info I posted up. They have given all their inter-company links. Collective holding over 3% and 1% thereafter have been declared. Individual holdings if below these thresholds don't have to be declared but have been referenced as linked.

apologies for going over old ground again on the subject of the VHCP holding and todays RNS:

'11. Additional information xvi
Bong Koh and Nimish Shah are the voting members of VHCP Management II, LLC and VHCP Management III, LLC. They have a notifiable interest in excess of 5% of the voting rights of Synairgen plc as notified on 7 August 2020.

VCHP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and manager of VHCP Co-Investment Holdings II, LLC, each of which holds shares in Synairgen plc falling below the notifiable threshold.

VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and manager of VHCP Co-Investment Holdings III, LLC, which in aggregate hold shares in Synairgen plc which represent 3.42% of the voting rights.

All percentages are based on the notified current issued share capital of Synairgen plc of 149,433,442 ordinary shares.'
https://www.investegate.co.uk/synairgen-plc--sng-/rns/holding-s--in-company/202008100950556416V/

Now I stand to be corrected but it does look like their total holding is only 5.09% (1.67% + 3.42%) which is held as follows:

VHCPII = 1.67%
This is split between VHCP Investment Holdings II and Venrock Healthcare Cap Partners II
As the total is below 3% they don't have to declare how much each holds.

VHCP III = 3.42%
This is split between Venrock Healthcare Cap Partners III (3.11%) and as this is above 3% it had to be reported.
VHCP Co-Investment Holdings III (0.31%) as this is under 3% it was not reported.

Their TR dates holdings crossed were:
24 July 0 to 3.25%
29 July 3.25% to 4.44%
5 Aug 4.44% to 5.09%
and on 6 August they obviously then allocated out the shares to the various companies/funds in the group, hence todays RNS.